Cargando…

P951: CLINICAL AND LABORATORY CHARACTERISTICS, COURSE AND OUTCOME OF COVID19 INFECTION IN PATIENTS WITH MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales:	Sretenovic, A., Mitrovic, M., Adzic Vukicevic, T., Bukumiric, Z., Markovic, O., Zdravkovic, M., Antic, D., Bila, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429179/ http://dx.doi.org/10.1097/01.HS9.0000846672.59631.15

Ejemplares similares

PB2103: PROGNOSTIC PROFILING OF PATIENTS WITH MULTIPLE MYELOMA: THE GAME OF SCORES-DOES IT MATTER?
por: Sretenovic, Aleksandra, et al.
Publicado: (2023)

PB2143: PROGNOSTIC SIGNIFICANCE AND CLINICAL APPLICABILITY OF THE COMORBIDITY INDICES IN PATIENTS WITH MULTIPLE MYELOMA: IMWG AND SARC-F SCORE
por: Vukosavljevic, Nikola, et al.
Publicado: (2023)

951. Weight Gain Associated With Antiretroviral Therapy
por: Patel, Yesha, et al.
Publicado: (2020)

P951: IMPACT OF MEASURABLE RESIDUAL DISEASE (MRD) DIFFERENCES ON PROGRESSION-FREE SURVIVAL (PFS): AN AGGREGATE DATA ANALYSIS FROM RANDOMIZED CLINICAL TRIALS IN MULTIPLE MYELOMA (MM)
por: Paiva, Bruno, et al.
Publicado: (2023)

P956: VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM (R2-ISS) FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA IN A REAL WORLD COHORT: AN ANALYSIS BY THE BALKAN MYELOMA STUDY GROUP (BMSG)
por: Kastritis, Efstathios, et al.
Publicado: (2023)

P1692: PREDICTIVE MODEL FOR VEIN THROMBOEMBOLIC EVENTS DEVELOPMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Mitrovic, M., et al.
Publicado: (2022)

P981: DISEASE CHARACTERISTICS AND TREATMENT OUTCOMES OF MYELOMA PATIENTS <50 YEARS OF AGE: AN ANALYSIS OF THE BALKAN MYELOMA STUDY GROUP
por: Kastritis, Efstathios, et al.
Publicado: (2023)

Fungal Planet description sheets: 951–1041
por: Crous, P.W., et al.
Publicado: (2019)

Target Studies with BNL E951 at the AGS
por: Kirk, H G, et al.
Publicado: (2001)

951 The association between COVID19 infection and umbilical artery dopplers in growth-restricted pregnancies
por: Ona, Samsiya, et al.
Publicado: (2021)

951 Outbreak of Mixed fungemia in a Children's Hospital in the United States
por: Al-Zubeidi, Duha, et al.
Publicado: (2014)

Tensile Deformation and Fracture Behavior of Nickel-Based Superalloy DZ951G
por: Guo, Chenhao, et al.
Publicado: (2021)

P1368: OUTPATIENT AUTOTRANSPLANTS FOR PERSONS WITH MULTIPLE MYELOMA
por: Sánchez-Raga, J. M., et al.
Publicado: (2022)

Draft Genome Sequence of a Rare Smut Relative, Tilletiaria anomala UBC 951
por: Toome, Merje, et al.
Publicado: (2014)

P963: EXTRAMEDULLARY MULTIPLE MYELOMA: CLINICAL CHARACTERISTICS, IMPACT, AND OUTCOMES IN A COHORT OF PATIENTS IN MEXICO
por: Llorente Chávez, Amaya, et al.
Publicado: (2023)

P25 EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP
por: Fazio, F., et al.
Publicado: (2023)

Draft Genome Assembly of Filamentous Brackish Cyanobacterium Limnoraphis robusta Strain CS-951
por: Willis, Anusuya, et al.
Publicado: (2015)

POS-951 THE EVOLVING PRACTICE OF NEPHROLOGY DURING THE COVID-19 PANDEMIC IN BRUNEI DARUSSALAM
por: LIM, C.Y., et al.
Publicado: (2022)

P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI
por: Mateos, M, et al.
Publicado: (2023)

P04 MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
por: Fazio, F., et al.
Publicado: (2023)

P851: TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA
por: Hasan Bou Issa, L., et al.
Publicado: (2022)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
por: Muñoz, Maria Nieves Lopez, et al.
Publicado: (2023)

P800: CHARACTERIZATION OF REGULATORY T CELLS IN PATIENTS WITH MULTIPLE MYELOMA
por: Kim, Sojeong, et al.
Publicado: (2023)

P26: EXTRAMEDULLARY MULTIPLE MYELOMA: A MONOCENTRIC RETROSPECTIVE OBSERVATIONAL STUDY
por: Brescini, M, et al.
Publicado: (2022)

Assessment of Aspartame (E951) Occurrence in Selected Foods and Beverages on the German Market 2000–2022
por: Schorb, Sydney, et al.
Publicado: (2023)

P855: SYNERGISTIC EFFICACY OF COMBINED SUMOYLATION AND PROTEASOME INHIBITION IN MULTIPLE MYELOMA
por: Keller, U., et al.
Publicado: (2022)

P971: EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP.
por: Fazio, Francesca, et al.
Publicado: (2023)

P08 TEMPORAL TRENDS IN PROGNOSIS OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA (SMM) WHO MEET CRITERIA FOR BIOMARKER-DEFINED EARLY MULTIPLE MYELOMA (SLIM CRAB POSITIVE MM)
por: Ludwig, H., et al.
Publicado: (2023)

P976: BENDAMUSTINE-POMALIDOMIDE-DEXAMETHASONE (BPD) FOR RELAPSED AND/OR REFRACTOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE
por: Yuping, Z., et al.
Publicado: (2022)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

P977: THE VENOUS THROMBOEMBOLISM RISK ASSESMENT MODELS IN MULTIPLE MYELOMA
por: Alp Kirkizlar, Tugcan, et al.
Publicado: (2023)

P850: THE EFFECT OF UROLITHIN PRODUCTION BY GUT MICROBIOTA IN MULTIPLE MYELOMA
por: Rodríguez-García, Alba, et al.
Publicado: (2023)

P927: CLINICAL CHARACTERISTICS, SURVIVAL OUTCOMES AND PROGNOSIS IN 123 IMMUNOGLOBULIN D MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE SINGLE-CENTER
por: Liu, J., et al.
Publicado: (2022)

The emergence of non-secretory multiple myeloma during the non-cytotoxic treatment of essential thrombocythemia: a case report
por: Leković, Danijela, et al.
Publicado: (2013)

P1653: INFLAMMATION MEDIATED THROMBUS FORMATION IN LYMPHOMAS
por: Antic, Darko, et al.
Publicado: (2023)

Knowledge and use of antibiotics among health care users in Institute of public health of Belgrade
por: Belamaric, G, et al.
Publicado: (2022)

P02: PROGNOSTIC STRATIFICATION OF STANDARD RISK MULTIPLE MYELOMA DEFINED BY REVISED ISS
por: Barilà, G, et al.
Publicado: (2022)

P48 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE REAL-LIFE EXPERIENCE OF THE REGIONAL TUSCAN MYELOMA NETWORK (RTM)
por: Attucci, I., et al.
Publicado: (2023)

The flavonoid beverage Haelan 951 induces growth arrest and apoptosis in pancreatic carcinoma cell lines in vitro
por: Rothe, Juliane, et al.
Publicado: (2015)

P830: IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA
por: Thomas Iannozzi, Nicolas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cqjnf4kslemcr4mjf6npgo9109